Bariatric-Metabolic Surgery for Non-Alcoholic Fatty Liver Disease

M Eilenberg¹, G Prager¹ and K Staufer²*

¹Division of General Surgery, Department of Surgery, Medical University of Vienna, Austria
²Division of Transplantation, Department of Surgery, Medical University of Vienna, Austria

*Corresponding Author: K Staufer, Associate Professor, Division of Transplantation, Department of Surgery, Medical University of Vienna, Vienna, Austria.

Received: March 25, 2018; Published: June 07, 2018

Non-alcoholic fatty liver disease (NAFLD) and obesity are closely linked. Up to 90% of obese patients suffer from NAFLD which may progress to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma [1,2]. NAFLD has become the leading cause of chronic liver disease and is estimated to become the most common indication for liver transplantation in the near future [3,4]. An effective treatment of NAFLD in most cases is dependent on significant weight loss, which may be achieved by lifestyle modification, pharmaceutical therapy or bariatric-metabolic surgery [5]. Bariatric-metabolic surgery may achieve sustained significant weight loss, leading to a decline of the metabolic syndrome and improvement or reversibility of NAFLD in up to 84% of patients [6,7].

In respect of liver disease weight loss of more than 10% is required to achieve therapeutic success, which may be reached in almost all patients who undergo bariatric-metabolic surgery [8]. Depending on the procedure a long-term percentage excess weight loss between 47 and 64% is expected [9]. The combined restrictive and malabsorptive procedure Roux-en-Y gastric bypass (RYGB) has shown a significant superiority regarding hepatic improvements in comparison to the purely restrictive gastric band after 5 years of surgery [10,11]. Even in advanced fibrosis an improvement or reversal was possible in 55% of all patients undergoing RYGB [12]. In contrast, after extensive malabsorption as in biliopancreatic diversion (BPD) or jejunoileal bypass (JIB) a progression of liver fibrosis was reported in few patients [13,14]. A fulminant liver failure after bariatric surgery is very rare and was mainly described after BPD and JIB [15]. However, we recently reported that severe liver dysfunction may also occur after the nowadays commonly performed RYGB and One-anastomosis gastric bypass (OAGB) including ascites, impairment of coagulation parameters and progression of liver fibrosis to advanced stages including cirrhosis [16]. The reason for this liver deterioration in single patients remains currently unknown. Up to 5% of the bariatric patients suffer from asymptomatic cirrhosis, only diagnosed during their operation [17]. In patients with preexisting liver cirrhosis an increased perioperative liver-related morbidity exists and early mortality, especially in decompensated liver cirrhosis, has been reported to be as high as 1.6% [18]. Jan., et al. showed that restrictive procedures did not lead to an increased liver-related mortality and that complication rates were reduced in comparison to malabsorptive methods in patients with cirrhosis [18].

The present data suggest, that the preoperative diagnostic work-up and the individual selection of the applied bariatric-metabolic procedure is vital for patients with obesity and preexisting liver disease. Equally important is the follow-up after bariatric-metabolic surgery with an increased attention towards a possible postoperative deterioration of liver function.

Bariatric-metabolic surgery is an excellent therapeutic approach in order to achieve sustained weight loss and improve or reverse NAFLD in most patients. A postoperative deterioration of NAFLD seems to be rare, but may occur mainly after highly malabsorptive procedures. In preexisting cirrhosis a restrictive procedure should be preferred.

Citation: K Staufer, et al. "Bariatric-Metabolic Surgery for Non-Alcoholic Fatty Liver Disease". EC Gastroenterology and Digestive System 5.7 (2018): 466-468.
Bibliography


2. Lam B and ZM Younossi. "Treatment options for nonalcoholic fatty liver disease". *Therapeutic Advances in Gastroenterology* 3.2 (2010): 121-137.


*Citation*: K Staufer., et al. "Bariatric-Metabolic Surgery for Non-Alcoholic Fatty Liver Disease". *EC Gastroenterology and Digestive System* 5.7 (2018): 466-468.
Bariatric-Metabolic Surgery for Non-Alcoholic Fatty Liver Disease


Volume 5 Issue 7 July 2018
©All rights reserved by K Staufer, et al.